Proteomics

Dataset Information

0

Dataset11_DLBCL clinical sample 1 5h Gemcitabine ITDR


ABSTRACT: Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Liang Ying Yu 

PROVIDER: PXD054909 | JPOST Repository | Thu Jun 12 00:00:00 BST 2025

REPOSITORIES: jPOST

Dataset's files

Source:
Action DRS
20230112_YY_SLS1428_37C_FR1.raw Raw
20230112_YY_SLS1428_37C_FR2.raw Raw
20230112_YY_SLS1428_37C_FR3.raw Raw
20230112_YY_SLS1428_37C_FR4.raw Raw
20230112_YY_SLS1428_37C_FR5.raw Raw
Items per page:
1 - 5 of 20
altmetric image

Publications


Mechanisms for resistance to cytotoxic cancer drugs are dependent on dynamic changes in the biochemistry of cellular pathways, information which is hard to obtain at the systems level. Here we use a deep functional proteomics implementation of the Cellular Thermal Shift Assay to reveal a range of induced biochemical responses to gemcitabine in resistant and sensitive diffuse large B cell lymphoma cell lines. Initial responses in both, gemcitabine resistant and sensitive cells, reflect known targ  ...[more]

Similar Datasets

2025-06-12 | PXD054910 | JPOST Repository
2025-06-12 | PXD054907 | JPOST Repository
2025-06-12 | PXD054908 | JPOST Repository
2025-06-12 | PXD054903 | JPOST Repository
2025-06-12 | PXD054901 | JPOST Repository
| PRJNA174200 | ENA
| PRJNA432939 | ENA
| PRJNA62899 | ENA
2007-08-30 | GSE3344 | GEO
2016-04-01 | E-GEOD-67257 | biostudies-arrayexpress